Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896026 | 0.85 | — | — | |
| SCHEMBL1149395 | 0.79 | PHGDH (0.48) | CPN1CPB2ALDH1A1NPC1MEN1 | |
| SCHEMBL14344826 | 0.79 | CPN1 (0.43) | CPN1CPB2F10 | |
| SCHEMBL3318800 | 0.79 | CPN1 (0.43) | CPN1CPB2NPC1F10 | |
| SCHEMBL14621736 | 0.78 | CPN1 (0.47) | CPN1CPB2MEN1KMT2AF10 | |
| SCHEMBL3895895 | 0.77 | CPN1 (0.42) | CPN1CPB2F10 | |
| SCHEMBL14344742 | 0.77 | CPN1 (0.42) | CPN1CPB2F10 | |
| Hydrochloric Acid SCHEMBL7294339 | 0.77 | CPN1 (0.42) | CPN1CPB2F10 | |
| SCHEMBL8279747 | 0.77 | LMNA (0.52) | CPN1CPB2ALDH1A1NPC1 | |
| SCHEMBL8164590 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | claimed |
| US-7396844-B1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2008-07-08 | — | — | US | claimed |
| US-6825181-B1 | ORALLY ADMINISTRATED TO EXHIBIT A STRONG ANTICOAGULANT EFFECT BY INHIBITING ACTIVATED BLOOD- COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | claimed |
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | claimed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | claimed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | claimed |
| EP-1065200-A1 | AMINOISOQUINOLINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-01-03 | — | — | EP | claimed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | claimed |
| US-8227506-B2 | Benzamidine compound | AJINOMOTO., INC. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-7396844-B1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO. INC (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1847527-A1 | NOVEL BENZAMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2001070743-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-1065200-A1 | AMINOISOQUINOLINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | CPN1 1216/4885CPB2 23/4885EPHX2 2041/4885 |
| US-20030186969-A1 | Benzodiazepine derivatives | GABRA1, F11, GABRA4 | CPN1 3092/4885CPB2 544/4885EPHX2 2011/4885 |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | CPN1 1216/4885CPB2 23/4885EPHX2 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.